Skip to main content
Clinical Trials/JPRN-C000000413
JPRN-C000000413
Completed
Phase 3

Validation of genetic diagnosis to predict sensitivity in primary systemic chemotherapy with paclitaxel in women with breast cancer - Validation of genetic diagnosis to predict sensitivity in primary systemic chemotherapy with paclitaxel in women with breast cancer (GENESIS-BC-01)

Cancer Institute Hospital, Japanese Foundation for Cancer Research0 sites109 target enrollmentMay 1, 2006
ConditionsBreast cancer

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Breast cancer
Sponsor
Cancer Institute Hospital, Japanese Foundation for Cancer Research
Enrollment
109
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 1, 2006
End Date
July 1, 2012
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Cancer Institute Hospital, Japanese Foundation for Cancer Research

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Non invasive or microinvasive breast cancer. Stage IIIC, IV. Inflammatory breast caner. Male breast cancer. Previously treated with chemotherapy, hormone therapy or radiotherapy. Active double cancer. Serious complication (infection, cardiac disease, pulmonary fibrosis interstitial pneumonitis, bleeding). Hepatitis type B and its carrier. Uncontrolled diabetes. Heavy history of drug allergy. History of allergic reaction to drugs using the vehicle Cremophor. Pregnant, nursing or willing to be pregnant. Inadequate to entry judged by investigators.

Outcomes

Primary Outcomes

Not specified

Similar Trials